Trial · NCT07913399
Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
NCT07913399, Not applicable, Not yet recruiting, Medipol University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis. Trials, record NCT07913399. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913399
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
- NCT number
- NCT07913399
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Medipol University
- Conditions
- Chronic Apical Periodontitis, Pulp Necrosis
- Interventions
- Conventional Root Canal Treatment, Regenerative Endodontic Treatment with i-PRF, Injectable Platelet-Rich Fibrin (i-PRF)
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Periapical Radiographic Healing Evaluated by Modified Periapical Index (PAI) Score | Baseline and 6 months post-treatment | Radiographic evaluation of periapical tissue status and bone healing on standardized parallel periapical radiographs using the unabbreviated Modified Periapical Index (PAI) scale. The PAI is a 5-point scale ranging from 1 to 5: minimum value = 1 (normal periapical structure / complete healing / best outcome), maximum value = 5 (severe periodontitis with exacerbating features / worse outcome). Higher scores represent worse periapical status (worse outcome). |
| Primary | Clinical Treatment Success Rate | 6 months post-treatment | Percentage of participants achieving complete clinical treatment success, defined as the absence of all clinical signs and symptoms (spontaneous pain, tenderness to percussion, tenderness to palpation, swelling, and sinus tract) along with normal tooth function. |
| Secondary | Postoperative Pain Intensity Evaluated by Visual Analog Scale (VAS) | 12 hours, 24 hours, Day 3, and Day 7 after the second treatment session | Self-reported postoperative pain intensity measured using the unabbreviated Visual Analog Scale (VAS). The VAS is a 10-point scale ranging from 0 to 10: minimum value = 0 (no pain / best outcome), maximum value = 10 (worst imaginable pain / worse outcome). Higher scores represent higher pain intensity (worse outcome). |
| Secondary | Analgesic Consumption | From the second treatment session to Day 7 | Number of ibuprofen tablets taken after treatment will be recorded based on patient diaries. |
| Secondary | Pulp Vitality Response | 6 months after treatment | Recovery of pulp vitality will be evaluated using cold testing and electric pulp testing (EPT). EPT measurements will be performed twice and the numerical values will be recorded. Responses will be categorized as normal, sensitive, dull, or no response. |
| Secondary | Gingival Crevicular Fluid Inflammatory Biomarkers | Baseline and 6 months | Levels of IL-1β, IL-6, and TNF-α in gingival crevicular fluid will be measured and compared between baseline and the 6-month follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913399
GET https://conductscience.org/api/trials/v1/NCT07913399/registered